Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study

被引：0
|
作者：
Li Ying
Ji Suyun
Liang Yanhua
Liang Yunsheng
Deng Li
Dang Lin
Lv Chengzhi
Lin Bingjiang
Zhang Furen
Shi Wendi
Li Jinnan
Dong Yu
Dou Guanshen
Yuling Shi
机构：
[1] Tongji University School of Medicine,Department of Dermatology, Shanghai Skin Disease Hospital
[2] Southern Medical University,Department of Dermatology, Dermatology Hospital
[3] Southern Medical University,Department of Dermatology, Cosmetology and Venereology, Shenzhen Hospital
[4] Longgang Central Hospital of Shenzhen,Department of Dermatology
[5] Dalian Skin Disease Hospital,Department of Dermatology
[6] Ningbo First Hospital,Department of Dermatology
[7] Shandong First Medical University & Shandong Academy of Medical Sciences,Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology
[8] Eli Lilly and Company,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Efficacy; Ixekizumab; Psoriasis; Real world; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5464 / 5474
页数：10
相关论文
共 50 条
  • [1] Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study
    Ying, Li
    Suyun, Ji
    Yanhua, Liang
    Yunsheng, Liang
    Li, Deng
    Lin, Dang
    Chengzhi, Lv
    Bingjiang, Lin
    Furen, Zhang
    Wendi, Shi
    Jinnan, Li
    Yu, Dong
    Guanshen, Dou
    Shi, Yuling
    ADVANCES IN THERAPY, 2023, 40 (12) : 5464 - 5474
  • [2] Efficacy and Safety of Ixekizumab in Chinese Patients With Moderate-to-Severe Plaque Psoriasis: 60-Week Results From a Phase 3 Study
    Li Xia
    Zheng Jie
    Pan WeiLi
    Zheng Min
    Lu Yan
    Li FuQiu
    Ding YangFeng
    Zhang JianZhong
    Li HongYing
    Rui WenLong
    国际皮肤性病学杂志（英文）, 2022, 05 (04)
  • [3] Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis
    Egeberg, Alexander
    Bryld, Lars Erik
    Skov, Lone
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (01) : 173 - 178
  • [4] Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium
    Carmona-Rocha, Elena
    Puig, Lluis
    IMMUNOTHERAPY, 2023, 15 (15) : 1209 - 1225
  • [5] Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program
    Gulliver, Wayne
    Gooderham, Melinda J.
    Zhu, Baojin
    Jossart, Christian
    Montmayeur, Sonia
    Burge, Russel
    Reed, Catherine
    DERMATOLOGY AND THERAPY, 2023, 13 (01) : 235 - 244
  • [6] Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study
    Li, Ying
    Lv, Chengzhi
    Dang, Lin
    Lin, Bingjiang
    Tao, Juan
    Zhang, Chunlei
    Zhou, Xiaoyong
    Ma, Han
    Lu, Yi
    Chen, Rong
    Li, Jinnan
    Dou, Guanshen
    Liang, Yunsheng
    Liang, Yanhua
    Shi, Yuling
    DERMATOLOGY AND THERAPY, 2024, 14 (04) : 907 - 918
  • [7] Ixekizumab treatment in patients with moderate-to-severe plaque psoriasis in a real-world clinical setting
    Ogut, Neslihan Demirel
    Yildirim, Sema Koc
    Erbagci, Ece
    Hapa, Fatma Asli
    JOURNAL OF COSMETIC DERMATOLOGY, 2022, 21 (11) : 6215 - 6224
  • [8] Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis
    Vu, Trang T.
    Gooderham, Melinda
    Papp, Kim
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (11) : 1423 - 1433
  • [9] Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose Study
    Min Zheng
    Xiang Chen
    Feng Wang
    Jisu Chen
    Kimberley Jackson
    Fan Yang
    Christopher Payne
    HongYing Li
    YiHui Wang
    ZiPei Xiao
    Jie Zheng
    Advances in Therapy, 2023, 40 : 3804 - 3816
  • [10] Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose Study
    Zheng, Min
    Chen, Xiang
    Wang, Feng
    Chen, Jisu
    Jackson, Kimberley
    Yang, Fan
    Payne, Christopher
    Li, HongYing
    Wang, YiHui
    Xiao, ZiPei
    Zheng, Jie
    ADVANCES IN THERAPY, 2023, 40 (09) : 3804 - 3816
12345